3-(5-amino-2-(2-methyl-4-(2-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid | 1268527-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(5-amino-2-(2-methyl-4-(2-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid
• 英文别名: 3-[5-Amino-2-[2-[2-methyl-4-[2-[2-[2-(2-phosphonoethoxy)ethoxy]ethoxy]ethoxy]phenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid
• CAS: 1268527-06-5
• 化学式: C₃₂H₄₀N₃O₉P
• 分子量: 641.658
• InChiKey: KMXDAWHMOTZLTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  45
• 可旋转键数：
  19
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  184
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
  申请人：Wu Tom Yao Hsiang

  公开号：US20110053893A1

  公开（公告）日：2011-03-03

  The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

  这项发明提供了一类新型化合物，包括这类化合物的免疫原组合物和药物组合物，以及利用这类化合物治疗或预防与Toll样受体7相关的疾病或紊乱的方法。在一个方面，这些化合物可用作辅助剂，以增强疫苗的有效性。
• Formulation of immunopotentiators
  申请人：Singh Manmohan

  公开号：US20120177681A1

  公开（公告）日：2012-07-12

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以被吸附到不溶性金属盐中，例如铝盐，以修改它们的药代动力学、药效学、肌肉内滞留时间和/或免疫刺激作用。免疫增强剂被改性以引入一个基团，例如膦酸盐基团，可以介导吸附。即使以吸附形式传递，这些改性化合物也可以保留或改善它们在体内的免疫活性。
• ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
  申请人：Singh Manmohan

  公开号：US20130274465A1

  公开（公告）日：2013-10-17

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以吸附到不溶性金属盐上，例如铝盐，以改变它们的药代动力学、药效学、肌肉内滞留时间和/或免疫刺激作用。免疫增强剂被修改以引入一个基团，例如磷酸酯基团，可以介导吸附。即使以吸附形式输送，这些修改的化合物仍然可以保持或改善它们的体内免疫活性。
• Adsorption of immunopotentiators to insoluble metal salts
  申请人：Novartis AG

  公开号：EP2719395A1

  公开（公告）日：2014-04-16

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫促效剂可吸附在铝盐等不溶性金属盐上，以改变其药代动力学、药效学、肌内滞留时间和/或免疫刺激效果。对免疫增强剂进行改性，引入一个可介导吸附的分子（如膦酸基）。这些经过修饰的化合物即使以吸附形式给药，也能保持或提高其体内免疫活性。
• IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS
  申请人：Novartis AG

  公开号：EP2459216B1

  公开（公告）日：2013-10-30